Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical pharmacokinetics of hydralazine.

Literature DB >> 7047041

Clinical pharmacokinetics of hydralazine.

T M Ludden, J L McNay, A M Shepherd, M S Lin.

Abstract

Entities: Chemical

Mesh：

Substances：
Hydralazine

Year: 1982 PMID： 7047041 DOI： 10.2165/00003088-198207030-00001

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

101 in total

1. Studies on the control of hypertension by hyphex. IV. Levels of the agents in urine and blood.

Authors: H M PERRY; H A SCHROEDER; J D MORROW
Journal: Am J Med Sci Date: 1954-10 Impact factor: 2.378

2. Specific afterload reduction with parenteral hydralazine following cardiac surgery.

Authors: R N Sladen; M H Rosenthal
Journal: J Thorac Cardiovasc Surg Date: 1979-08 Impact factor: 5.209

3. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors:
Journal: JAMA Date: 1967-12-11 Impact factor: 56.272

4. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

Authors: D D Shen; J P Hosler; R L Schroder; D L Azarnoff
Journal: J Pharmacokinet Biopharm Date: 1980-02

5. Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.

Authors: R D Magorien; D W Triffon; C E Desch; W H Bay; D V Unverferth; C V Leier
Journal: Ann Intern Med Date: 1981-07 Impact factor: 25.391

6. Determination of hydralazine metabolites: 4-hydrazino-phthalazin-1-one and n-acetylhydrazinophthalazin-1-one by gas chromatography and s-triazolo[3,4-alpha]phthalazine and phthalazinone by high-performance liquid chromatography.

Authors: V Facchini; J A Timbrell
Journal: J Chromatogr Date: 1980-08-08

7. Polymorphic acetylation of hydralazine.

Authors: J A Timbrell; S J Harland; V Facchini
Journal: Clin Pharmacol Ther Date: 1980-09 Impact factor: 6.875

8. Afterload reduction with hydralazine following valve replacement.

Authors: J D Marco; J W Standeven; H B Barner
Journal: J Thorac Cardiovasc Surg Date: 1980-07 Impact factor: 5.209

9. Studies on the direct vasodilator effect of hydralazine in the isolated rabbit renal artery.

Authors: M Khayyal; F Gross; V A Kreye
Journal: J Pharmacol Exp Ther Date: 1981-02 Impact factor: 4.030

10. Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone.

Authors: T Talseth; K D Haegele; J L McNay; H B Skrdlant; W A Clementi; A M Shepherd
Journal: J Pharmacol Exp Ther Date: 1979-12 Impact factor: 4.030

15 in total

Review 1. Guide to drug dosage in renal failure.

Authors: W M Bennett
Journal: Clin Pharmacokinet Date: 1988-11 Impact factor: 6.447

Review 2. The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.

Authors: I Walter-Sack
Journal: Klin Wochenschr Date: 1987-11-02

Clinical pharmacokinetics of hydralazine.

1. Studies on the control of hypertension by hyphex. IV. Levels of the agents in urine and blood.

2. Specific afterload reduction with parenteral hydralazine following cardiac surgery.

3. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

4. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

5. Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.

6. Determination of hydralazine metabolites: 4-hydrazino-phthalazin-1-one and n-acetylhydrazinophthalazin-1-one by gas chromatography and s-triazolo[3,4-alpha]phthalazine and phthalazinone by high-performance liquid chromatography.

7. Polymorphic acetylation of hydralazine.

8. Afterload reduction with hydralazine following valve replacement.

9. Studies on the direct vasodilator effect of hydralazine in the isolated rabbit renal artery.

10. Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone.

Review 1. Guide to drug dosage in renal failure.

Review 2. The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.

3. Human pharmacokinetics of cadralazine: a new vasodilator.

4. Assay for hydralazine as its stable p-nitrobenzaldehyde hydrazone.

Review 5. Extrahepatic metabolism of drugs in humans.

6. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?

7. Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.

8. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.

Review 9. First-pass elimination. Basic concepts and clinical consequences.

10. Pharmacokinetics of oral hydralazine in chronic heart failure.